AstraZeneca drops or divests a slate of drugs in latest quarterly update; Pierre Fabre extends a diagnostic collaboration with Roche

→ With profits in decline as generic Crestor competition bits into its cash flow, AstraZeneca noted the end of several in-house programs today as they cut some early-stage efforts and indicated the divestiture of others. Two mid-stage drugs are gone from the pipeline, with the rheumatoid arthritis drug mavrilimumab now at Kiniksa and inebelizumab handed off to their spinout Viela. MEDI-565, a BiTE partnered with Amgen, is out, along with the Sjögren’s syndrome  drug MEDI4920 (divested) and MEDI7734 as well as the atopic dermatitis therapy MEDI9314.

→ France’s Pierre Fabre is extending a collaboration agreement with Roche on a companion diagnostic for W0101, their new antibody drug conjugate targeting Insulin-like Growth Factor 1 (IGF-1) receptor now in a Phase I/II clinical study in patients with relapsed or refractory solid tumors.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 34,900+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Investment Analyst
SV Health Investors Boston, MA
Research Scientist - Disease Biology
Recursion Pharmaceuticals Salt Lake City, UT
Senior Scientist - Predictive Pharmacology
Recursion Pharmaceuticals Salt Lake City, UT
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA
Director of Marketing
twoXAR Mountain View, CA

Visit Endpoints Careers ->